BridgeMD
Methotrexate treatment in hand osteoarthritis refractory to usual treatments
EU CTIS ID: 2022-502362-24-00
What this study is testing
Compare the efficacy of subcutaneous Methotrexate 15mg/week vs. placebo on the evolution of the disease. joint structure at 12 months in patients with erosive digital osteoarthritis
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Age between 40 and 85
- Digital osteoarthritis (IPD and IPP) according to ACR criteria (with a hand X-ray less than 3 months old, showing at least 3 joints with digital osteoarthritis KL>=2) and symptomatic for more than three months
- At least one radiographically confirmed erosive hand joint with a pain VAS (patient) greater than 40 according to OARSI criteria
- Presence of at least one active synovitis on B-mode ultrasonography
You likely can't join if
- Injection of hyaluronic acid within the last 6 months
- Pregnant or breast-feeding women (a urine pregnancy test will be carried out in women of childbearing age
- Injection of cortisone derivatives within the previous 3 months
- Presence of psoriasis
- Inflammatory rheumatism
- Contraindications to the use of methotrexate
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.